| Literature DB >> 32423330 |
Honglei Ren1, Ranran Han1, Xuemei Chen2, Xi Liu3, Jieru Wan1, Limin Wang4, Xiuli Yang1, Jian Wang2.
Abstract
Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality and disability but no specific or effective treatment. In the last two decades, much has been learned about the pathologic mechanisms of ICH. It is now known that after ICH onset, immune and inflammatory responses contribute to blood-brain barrier disruption, edema development, and cell death processes, jointly resulting in secondary brain injury. However, the translation of potential therapies from preclinical to clinical success has been disappointing. With the development of new laboratory technology, recent progress has been made in the understanding of ICH pathomechanisms, and promising therapeutic targets have been identified. This review provides an update of recent progress on ICH and describes the prospects for further preclinical studies in this field. Our goal is to discuss new therapeutic targets and directions for the treatment of ICH and promote the effective transformation from preclinical to clinical trials.Entities:
Keywords: Intracerebral hemorrhage; immune interventions; inflammation; microglia; secondary injury
Year: 2020 PMID: 32423330 PMCID: PMC7446569 DOI: 10.1177/0271678X20923551
Source DB: PubMed Journal: J Cereb Blood Flow Metab ISSN: 0271-678X Impact factor: 6.200